Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid.

ABSTRACT:

Objectives

Tedizolid phosphate is a novel antibacterial under investigation for the treatment of gram-positive infections. This study was conducted to assess the pharmacokinetics, safety, and tolerability of intravenous tedizolid phosphate as well as the oral bioavailability of tedizolid phosphate.

Design

Double-blind, single-ascending dose, multiple-dose pharmacokinetics study, as well as tolerability and open-label crossover studies.

Setting

Single center in the United States (Covance Clinical Research Unit, Madison, WI) between September 2009 and January 2010.

Participants

Ninety healthy volunteers.

Intervention

Single intravenous (IV) doses of tedizolid phosphate 50 mg (lead-in) and 100-400 mg. Single oral and IV dose of tedizolid phosphate 200 mg in

SUBMITTER: Flanagan S 

PROVIDER: S-EPMC4260119 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature